Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGTA-145 safety and mobilization in healthy volunteers
NCT03932864Phase 1Completed
- Sponsor
- Ensoma
- Start
- Apr 2019
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MGTA-145 in hematopoietic stem cell mobilization (6 arms), sponsored by Ensoma. Primary endpoint: Incidence of treatment-emergent adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) at 28 days. Started Apr 2019; status: completed.
02
Drugs
MGTA-145
03
Conditions
hematopoietic stem cell mobilization
Beyond the preview
Go deeper on NCT03932864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932864.